Status:

COMPLETED

Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery

Lead Sponsor:

University of Miami

Conditions:

Endometrial Cancer

Eligibility:

FEMALE

18-80 years

Phase:

PHASE1

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy use...

Detailed Description

OBJECTIVES: * Determine a recommended phase II dose of adjuvant whole-abdominal radiotherapy when administered with cisplatin in patients with optimally debulked stage III or IV carcinoma of the endo...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of endometrial cancer, including any of the following cellular types:
  • Papillary serous carcinoma
  • Clear cell carcinoma
  • Adenocarcinoma
  • Stage III or IV disease
  • No evidence of extra-abdominal extension of disease (e.g., groin nodes, lung, or supraclavicular nodes)
  • Has undergone total-abdominal hysterectomy, surgical removal of any present fallopian tube and ovary, and resection of any palpable lymph nodes in the pelvis and para-aortic region (or surgical sampling of these nodal regions if no palpable nodes were present) within the past 6 weeks
  • Peritoneal washings must have been collected for cytological evaluation
  • Must have ≤ 1 cm residual disease after surgery
  • PATIENT CHARACTERISTICS:
  • Karnofsky performance status 60-100%
  • Life expectancy ≥ 6 months
  • WBC ≥ 3,000/mm\^3
  • Granulocyte count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Creatinine \< 2.0 mg/dL
  • Bilirubin \< 1.5 times upper limit of normal (ULN)
  • Lactate dehydrogenase \< 3 times ULN
  • Gamma glutamyl transferase \< 3 times ULN
  • SGPT and SGOT \< 3 times ULN
  • Alkaline phosphatase \< 3 times ULN
  • No other malignant tumor within the past 5 years
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No prior radiotherapy to the whole abdomen and/or pelvis/vagina
  • No systemic chemotherapy within the past 5 years

Exclusion

    Key Trial Info

    Start Date :

    May 1 2002

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 1 2011

    Estimated Enrollment :

    12 Patients enrolled

    Trial Details

    Trial ID

    NCT00448643

    Start Date

    May 1 2002

    End Date

    March 1 2011

    Last Update

    December 15 2016

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Miami Sylvester Comprehensive Cancer Center - Miami

    Miami, Florida, United States, 33136